Promising News from Major Medical Meeting, EULAR
Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […]
Grant Updates
The Lupus Research Alliance supports the full range of research from fundamental through translational and clinical studies. Most recently, the organization awarded six Novel Research Grants and seven Target Identification in Lupus (TIL) grants. PROMISING NOVEL GRANT AWARDS: The Lupus Research Alliance supports game-changing lupus research, and our Novel Research Grant program is exploring lupus […]
Q&A with Selena Gomez
Q: Why are you supporting the LRA’s Lift Up Lupus campaign? A: This was a tough year for all of us, and I am inspired by the sense of optimism conveyed by the LRA’s Lift Up Lupus campaign – and incredibly inspirational stories. There are many misconceptions surrounding lupus, and I hope the Lift Up […]
LRA Addressing Health Disparities Among Vulnerable Groups
February 20, 2020 The Lupus Research Alliance (LRA) works hard, often in concert with organizations like the National Minority Quality Forum to alleviate disparities in healthcare among groups at particular risk for lupus, including African-Americans as the group hardest hit by the disease. Several programs educate healthcare providers, patients and the public to better recognize […]
Meet Unstoppable Advocate for Minority Health Christopher Reed
Determined to alleviate healthcare disparities for minorities, J. Christopher Reed, JD, urges our lupus community to use the power of National Minority Health Month to spotlight the issue this April. First diagnosed at 16, Christopher fought debilitating lupus symptoms to graduate college in eight years and then Tulane University Law School in three. Throughout college […]
Catalyzing Research
First Lupus Nephritis Drug Approved In December of 2020, lupus research attained another major milestone-one which stemmed from a critical investigation funded by our organization. Now, with the FDA’s approval, belimumab (Benlysta®) can be used as a therapeutic for lupus nephritis. “An effective treatment developed specifically for lupus nephritis has been desperately needed,” commented Lupus […]
Two New Drugs Receive FDA Approval
May 1, 2021 “This is a historic moment in lupus with two new drug approvals for lupus nephritis just over a month,” enthused Kenneth M. Farber, LRA President and CEO. The LRA is excited to share that the U.S. Food and Drug Administration (FDA) has approved the use of voclosporin (Lupkynis™) as the first oral […]
Accelerating Medicines Partnership Completes Key Phase
September 24, 2019 The Accelerating Medicines Partnership (AMP) RA/Lupus Program, a joint effort involving the National Institutes of Health (NIH), the Foundation for NIH, pharmaceutical companies, and non-profit organizations such as the Lupus Research Alliance, has reached a milestone, finishing an important phase of its studies. Researchers with the AMP RA/Lupus Program have published a […]
Investigational CAR T Cell Gets Fast Tracked by U.S. FDA
May 1, 2023 The LRA and our clinical arm Lupus Therapeutics are pleased to share good news from Cabaletta Bio, Inc. that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CABA-201, a CAR T cell investigational therapy in development to treat systemic lupus erythematosus and lupus nephritis – a common […]
Results of Two Voclosporin Trials Presented at Key Medical Meeting
October 22, 2020 Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis. Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, […]
New TIL Grantees Offer Novel Approaches
Sept. 7, 2017. Grantees of our Target Identification in Lupus (TIL) program are remarkable scientific investigators whose ingenuity and determination are bringing new insights to lupus research. The Lupus Research Alliance congratulates each of these brilliant researchers in their quest to expand our understanding of lupus and ways to defeat it: Kerstin Nundel, PhD University […]
Data Shows Voclosporin Preserves Kidney Function for Three Years
July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis. These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the […]